Circulating Biomarkers of Interstitial Lung Disease in Systemic Sclerosis

• Published in: International Journal of Rheumatology Vol. 2012; no. 2012; pp. 6 - 15
• Main Authors: Lota, Harpreet K., Renzoni, Elisabetta A.
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Limiteds 01-01-2012; Hindawi Puplishing Corporation; Hindawi Publishing Corporation; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Biomarkers; Clinical trials; Extracellular matrix; Gene expression; Lung diseases; Medical prognosis; Mortality; Multivariate analysis; Pathogenesis; Peptides; Proteins; Pulmonary fibrosis; Pulmonary hypertension; Review; RNA polymerase; Rodents; Studies
• ISSN: 1687-9260; 1687-9279
• DOI: 10.1155/2012/121439

Interstitial lung disease (ILD) is a major cause of morbidity and mortality in patients with systemic sclerosis (SSc). Although a large proportion of SSc patients have only limited interstitial involvement with an indolent course, in a significant minority ILD is progressive, requiring prompt treatment and careful monitoring. One of the main challenges for the clinician treating this highly variable disease is the early identification of patients at risk of progressive ILD, while avoiding potentially toxic treatments in those whose disease is inherently stable. Easily available and repeatable biomarkers that allow estimation of the risk of ILD progression and early response to treatment are highly desirable. In this paper, we review the evidence for circulating biomarkers with potential roles in diagnosis, monitoring of disease activity, or determining prognosis. Peripheral blood biomarkers offer the advantages of being readily obtained, non-invasive, and serially monitored. Several possible candidates have emerged from studies performed so far, including SP-D, KL-6, and CCL18. Presently however, there are few prospective studies evaluating the predictive ability of prospective biomarkers after adjustment for disease severity. Future carefully designed, prospective studies of well characterised patients with ILD, with optimal definition of disease severity and outcome measures are needed.